Cadila Pharmaceuticals Appoints Anand Shetty CEO of Emerging Markets Across India, Russia, Africa and Southeast Asia

Anand Shetty has been appointed CEO of Emerging Markets at Cadila Pharmaceuticals Limited, with responsibility for India, Russia, Africa and Southeast Asia, the company said in a November 2026 announcement. Hrtoday reported the appointment, which the company framed around Shetty's more than three decades in pharmaceutical leadership, sales, marketing, business development and general management.

Shetty's Novo Nordisk and Ranbaxy Background

Shetty joins Cadila Pharmaceuticals after more than 23 years at Novo Nordisk, where he most recently served as Corporate Vice President with responsibility for the company's business across Southeast Asia. Earlier roles at Novo Nordisk included Vice President and General Manager in Indonesia, Vice President and General Manager and Managing Director/General Manager in Bangladesh, and Sales and Marketing Director and Sales Director in India. He also held positions as Zonal Manager, Regional Manager and Business Development Manager at the Danish drugmaker.

Before Novo Nordisk, Shetty spent nearly four years at RPG Life Sciences as Regional Manager and District Manager across markets including Tamil Nadu, Kerala, Pune, Kolhapur, Aurangabad and Goa. His earlier career includes more than six years at Ranbaxy, where he moved through district management roles across Ahmedabad, Maharashtra, Karnataka, Kerala and Goa, with responsibilities spanning sales, product launches and market development.

Cadila Pharmaceuticals' Scale and Portfolio

Cadila Pharmaceuticals was founded by Shri I.A. Modi and is headquartered in Ahmedabad, Gujarat. The company says it has developed and manufactured pharmaceutical products in India for over seven decades and distributes them across more than 100 countries, with a portfolio spanning more than 45 therapeutic areas across 12 specialties. Research and development covers biotechnology, APIs, formulations, plant tissue culture and phytochemistry, supported by more than 300 scientists, and manufacturing facilities operate in Gujarat, Jammu & Kashmir and Ethiopia.

According to akta.pro company records, Cadila Pharmaceuticals was founded in 1951 and lists 8,000+ employees, with a formulation portfolio of 850+ finished dosage products across 45 therapeutic areas and 12 specialities. The same records list Dr. Rajiv I. Modi as Chairman and Managing Director, Jawed Zia as Chief Executive Officer, Ketan Patel as Chief Information Officer and Sudendra Rao as Global CHRO.

Regulatory Scrutiny Before the Appointment

In August 2026, the Bombay High Court directed the Maharashtra Food and Drug Administration to act judiciously after Cadila Pharmaceuticals contested an order banning the sale of some of its medicines, The Times of India reported. The Indian Express reported in October 2026 that the Maharashtra FDA had cancelled sale and distribution licences of three Cadila Pharmaceuticals godowns in Pune, Nagpur and Thane after finding drugs with different active ingredients were sold under deceptively similar names to Aciloc.

In July 2026, Business Standard reported that Cadila Pharmaceuticals said no regulatory order prohibited the manufacture, sale or distribution of its Aciloc 150+ and Aciloc 300+ products, with supplies to pharmacies continuing uninterrupted.